Saad et al.'s review[
1], “Emerging trends in the management of non-obstructive azoospermia,” offers a compelling synthesis of cutting-edge diagnostic and therapeutic strategies for non-obstructive azoospermia (NOA), a challenging condition affecting 10%–15% of infertile men. By highlighting advances in whole exome sequencing (WES), biomarkers like Anti-Müllerian hormone (AMH) and microRNAs (miRNAs), and micro-dissection testicular sperm extraction (micro-TESE), the authors chart a path toward precision medicine in male infertility. Their exploration of AI and gene-editing technologies like CRISPR/Cas9 underscores the transformative potential of these innovations.
This review is significant, addressing the urgent need for prognostic tools in NOA, where micro-TESE success rates are 50%–60%. The focus on WES to identify genetic mutations (e.g., CFTR, TEX11) aligns with recent findings that WES uncovers novel spermatogenesis-related genes, improving diagnostic precision[
2]. Similarly, the discussion of miRNAs as non-invasive biomarkers for predicting sperm retrieval success is supported by studies like Zhang et al.[
3], which identified exosomal tRFs as predictive markers. The manuscript's strength lies in its synthesis of genomic and proteomic advances, offering a clear framework for personalized NOA management.
This article does more than summarize current knowledge—it challenges the field to refine and integrate these tools into practice. Future research should prioritize multicenter studies to validate biomarker thresholds, assess WES cost-effectiveness, and explore AI models for predicting micro-TESE outcomes, as demonstrated by Peng et al.'s neural network approach[
4]. Ethical and accessibility challenges in gene-editing therapies also warrant investigation.
The core message is clear: the future of NOA management lies in precision. As andrology increasingly embraces personalized approaches, this manuscript stands as a key resource for urologists, fertility specialists, and researchers striving to optimize care for male infertility.
PDF
(65KB)
